Compare JCSE & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JCSE | INDP |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 5.2M |
| IPO Year | 2022 | 2021 |
| Metric | JCSE | INDP |
|---|---|---|
| Price | $1.35 | $1.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 61.2K | 50.9K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | ★ 8.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $0.27 |
| 52 Week High | $2.50 | $13.24 |
| Indicator | JCSE | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 55.48 | 34.20 |
| Support Level | $1.02 | $1.71 |
| Resistance Level | $1.31 | $2.08 |
| Average True Range (ATR) | 0.09 | 0.28 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 63.64 | 1.18 |
JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The product lives of its cleaning systems and other equipment ranges from two to ten years. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. The company derives the majority of its revenue from the Sales of cleaning systems and other equipment. Geographically, the company derives a majority of its revenue from Singapore, followed by Malaysia.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.